Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH.

J Med Chem. 2012 Jun 14;55(11):5121-9. doi: 10.1021/jm300014q. Epub 2012 May 30.

PMID:
22575017
[PubMed - indexed for MEDLINE]
2.

Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH.

J Pharmacol Exp Ther. 2013 Mar;344(3):589-99. doi: 10.1124/jpet.112.199646. Epub 2012 Dec 11.

PMID:
23232447
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway.

Alge-Priglinger CS, André S, Schoeffl H, Kampik A, Strauss RW, Kernt M, Gabius HJ, Priglinger SG.

Biochimie. 2011 Mar;93(3):477-88. doi: 10.1016/j.biochi.2010.10.021. Epub 2010 Nov 20.

PMID:
21094672
[PubMed - indexed for MEDLINE]
4.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.

Cancer Treat Rev. 2014 Mar;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007. Epub 2013 Aug 1. Review.

PMID:
23953240
[PubMed - indexed for MEDLINE]
5.

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.

Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW.

Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15975-80. Epub 2006 Oct 16.

PMID:
17043243
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface.

Miller MC, Nesmelova IV, Platt D, Klyosov A, Mayo KH.

Biochem J. 2009 Jun 26;421(2):211-21. doi: 10.1042/BJ20090265.

PMID:
19432560
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene.

Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH.

Bioconjug Chem. 2010 Jan;21(1):20-7. doi: 10.1021/bc900287y.

PMID:
20020769
[PubMed - indexed for MEDLINE]
9.
10.

Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates.

André S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu FT, Liskamp RM, Gabius HJ.

Chembiochem. 2001 Nov 5;2(11):822-30.

PMID:
11948868
[PubMed - indexed for MEDLINE]
11.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M, Taraboletti G.

Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. doi: 10.1007/s00280-013-2270-2. Epub 2013 Aug 24.

PMID:
23978989
[PubMed - indexed for MEDLINE]
12.

Unique conformer selection of human growth-regulatory lectin galectin-1 for ganglioside GM1 versus bacterial toxins.

Siebert HC, André S, Lu SY, Frank M, Kaltner H, van Kuik JA, Korchagina EY, Bovin N, Tajkhorshid E, Kaptein R, Vliegenthart JF, von der Lieth CW, Jiménez-Barbero J, Kopitz J, Gabius HJ.

Biochemistry. 2003 Dec 23;42(50):14762-73.

PMID:
14674750
[PubMed - indexed for MEDLINE]
13.

Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.

Rapoport EM, André S, Kurmyshkina OV, Pochechueva TV, Severov VV, Pazynina GV, Gabius HJ, Bovin NV.

Glycobiology. 2008 Apr;18(4):315-24. doi: 10.1093/glycob/cwn009. Epub 2008 Feb 6.

PMID:
18256179
[PubMed - indexed for MEDLINE]
Free Article
14.
15.

Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.

Ito K, Scott SA, Cutler S, Dong LF, Neuzil J, Blanchard H, Ralph SJ.

Angiogenesis. 2011 Sep;14(3):293-307. doi: 10.1007/s10456-011-9213-5. Epub 2011 Apr 27.

PMID:
21523436
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Modulation of O-glycans and N-glycans on murine CD8 T cells fails to alter annexin V ligand induction by galectin 1.

Carlow DA, Williams MJ, Ziltener HJ.

J Immunol. 2003 Nov 15;171(10):5100-6.

PMID:
14607908
[PubMed - indexed for MEDLINE]
Free Article
17.

Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration.

Strik HM, Schmidt K, Lingor P, Tönges L, Kugler W, Nitsche M, Rabinovich GA, Bähr M.

Oncol Rep. 2007 Aug;18(2):483-8.

PMID:
17611674
[PubMed - indexed for MEDLINE]
18.
19.

Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity.

Nesmelova IV, Ermakova E, Daragan VA, Pang M, Menéndez M, Lagartera L, Solís D, Baum LG, Mayo KH.

J Mol Biol. 2010 Apr 16;397(5):1209-30. doi: 10.1016/j.jmb.2010.02.033. Epub 2010 Feb 23.

PMID:
20184898
[PubMed - indexed for MEDLINE]
20.

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Dings RP, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH.

Invest New Drugs. 2013 Oct;31(5):1142-50. doi: 10.1007/s10637-013-9932-0. Epub 2013 Feb 8.

PMID:
23392775
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk